Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204047
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(35,767) | $(30,021) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 270 | 302 |
| Stock-based compensation expense | 6,898 | 6,554 |
| Amortization of premium (accretion of discount) on investments, net | 162 | (882) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (679) | (575) |
Item 1. Financial Statements.
FAQ
- What is Oric Pharmaceuticals, Inc.'s D&A?
- Oric Pharmaceuticals, Inc. (ORIC) reported D&A of $270K in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Oric Pharmaceuticals, Inc.'s D&A decreased by 10.6% year-over-year, from $302K to $270K.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s D&A has grown at a 8.0% compound annual growth rate (CAGR), from $897K to $1.22M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Oric Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude